Fluorescence Imaging

NIH Grant R01CA109558 (PI Brian Pogue)

FLUORESCENCE IMAGING TO OPTIMIZE CANCER THERAPY

Molecular imaging to quantify tumor receptor activity has incredible potential for imaging extracellular protein signaling, yet many ligand molecules cannot be used effectively, because they do not differentiate between simple vascular permeability based uptake and true receptor binding. The development of methodologies which allow quantitative uptake of molecules in tumors is a primary focus of this grant in the renewal period. Fluorescence imaging of receptor activity in vivo is done using a novel Magnetic Resonance-guided Optical (MRgO) imaging instrument that is customized for small animals, with a primary focus on glioma tumor studies. The hardware and software sub- systems will be developed further to provide 4 layer volumetric data of fluorescence tomography guided by the MR data, and overlayed for visualization of the entire orthotopic tumor.

 

NIH Grant R01CA184354 (PI Scott Davis)

MRI FLUORESCENCE TOMOGRAPHY FOR QUANTIFYING TUMOR RECEPTOR CONCENTRATION IN VIVO

The abnormal expression of cell surface receptors on tumor cells has become a major focus of efforts to individualize cancer therapy. Receptors involved in cell proliferation and programmed death are commonly targeted with antibody therapies, and new treatment modalities seek to exploit this abnormality to preferentially deliver toxic payloads to tumor cells.  This project aims to advance a novel noninvasive MRI-coupled optical imaging approach that accounts for contrast agent pharmacokinetics and thus is capable of quantifying receptor concentration and availability in sub-surface tumors. Specifically, a novel, low cost multispectral fluorescence tomography system dedicated to MRI-guided dual tracer fluorescence tomography (MRg-DTFT) in preclinical MRI research scanners will be developed, validated and used to explore the molecular response to new cancer therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *